Intech Investment Management LLC Sells 82,887 Shares of Natera, Inc. $NTRA

Intech Investment Management LLC cut its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 97.1% in the second quarter, Holdings Channel.com reports. The institutional investor owned 2,482 shares of the medical research company’s stock after selling 82,887 shares during the quarter. Intech Investment Management LLC’s holdings in Natera were worth $419,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bank of Jackson Hole Trust bought a new stake in shares of Natera in the first quarter worth $29,000. Hilltop National Bank purchased a new position in Natera in the second quarter worth about $33,000. Oliver Lagore Vanvalin Investment Group bought a new stake in shares of Natera during the 2nd quarter valued at about $36,000. Northwestern Mutual Wealth Management Co. increased its position in shares of Natera by 83.5% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 106 shares during the last quarter. Finally, Summit Securities Group LLC bought a new position in shares of Natera in the 1st quarter worth approximately $39,000. 99.90% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NTRA has been the subject of several recent research reports. Morgan Stanley boosted their target price on shares of Natera from $195.00 to $220.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Wednesday, October 8th. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $240.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, November 25th. Stephens upped their price objective on Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Finally, BNP Paribas Exane raised Natera from an “underperform” rating to a “neutral” rating and set a $172.00 target price on the stock in a report on Monday, October 27th. Fifteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $220.88.

Natera Trading Up 3.3%

Shares of NTRA opened at $245.06 on Friday. The business’s 50 day moving average is $192.49 and its 200 day moving average is $170.77. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $241.28. The company has a market capitalization of $33.82 billion, a PE ratio of -107.01 and a beta of 1.75.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The company had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company’s quarterly revenue was up 34.7% compared to the same quarter last year. During the same period last year, the business earned ($0.26) earnings per share. Equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Activity at Natera

In related news, Director Roelof Botha sold 75,000 shares of the firm’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $236.12, for a total transaction of $17,709,000.00. Following the completion of the transaction, the director directly owned 1,154,198 shares of the company’s stock, valued at approximately $272,529,231.76. This trade represents a 6.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $166.62, for a total transaction of $499,860.00. Following the completion of the sale, the insider owned 120,859 shares in the company, valued at approximately $20,137,526.58. The trade was a 2.42% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 308,366 shares of company stock worth $63,050,068 in the last three months. Insiders own 5.63% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.